Articles tagged "Dosage"

2022 American Transplant Congress
Optimal Dose of Anti-Thymocyte Globulin to Improve Allograft and Patient Survival After Kidney Transplantation: Analysis from Korean Organ Transplantation Registry Data
Y. Shim, H. Kwon, Y. Kim, H. Kwon, J. Jung, Y. Ko, S. Lim, S. Shin
Surgery, Asan Medical Center, Seoul, Seoul, Korea, Republic of
*Purpose: The optimal dose of anti-thymocyte globulin (ATG) as an induction regimen in Asian kidney recipients is unclear.*Methods: Using Korean Organ Transplantation Registry database, we…
2022 American Transplant Congress
Reduction of Rabbit Anti-Thymocyte Globulin Dosing for Induction of Kidney Transplant During the COVID-19 Pandemic
C. Burrelli¹, S. Gundling¹, D. Ecabert¹, R. Powell¹, A. Padiyar¹, K. Andreoni¹, K. Chavin², A. Bixby¹
¹University Hospitals Cleveland Medical Center, Cleveland, OH, ²University Hospitals Cleveland Medical Center / Case Western Reserve, Cleveland, OH
*Purpose: Rabbit anti-thymocyte globulin (rATG) is a polyclonal antibody utilized for induction immunosuppression in high immunologic risk kidney transplant recipients. However, the optimal total dose…
2022 American Transplant Congress
Real-Life Tacrolimus Levels Are Associated with Biopsy-Proven Acute Rejection After the First Year Post-Kidney Transplantation
S. Meziyerh, T. van Gelder, D. van der Helm, P. J. van der Boog, J. W. de Fijter, D. J. Moes, A. P. de Vries
LUMC, Leiden, Netherlands
*Purpose: Evidence to recommend specific target concentrations for immunosuppression beyond the first year of kidney transplantation (KT) is limited. We correlated real-life exposure data of…
2022 American Transplant Congress
Conversion of Tacrolimus Immediate Release to LCP Tacrolimus in Obese Kidney Transplant Recipients
J. Newman, N. Patel, S. Patel, T. Sprague, E. Andrade, N. Rao, F. Bartlett, D. DuBay, V. Rohan, M. Casey, D. Taber
MUSC, Charleston, SC
*Purpose: Data describing the safety, efficacy and conversion ratio of tacrolimus immediate release (IR) to LCP-tacrolimus (LCP) in obese patients (BMI > 30) is lacking.…
2022 American Transplant Congress
Artificial Intelligence Based Dosing of Tacrolimus in Liver Transplantation: Prospective, Randomized Phase 2 Trial
A. Zarrinpar¹, C. Ho², C. Warren¹, J. Khong², M. Lee², S. Duarte¹, K. Andreoni¹, M. Johnson¹, N. Battula³, D. McKimmy¹, T. Beduschi¹
¹Surgery, University of Florida, Gainesville, FL, ²Mechanical and Aerospace Engineering, University of California, Los Angeles, CA, ³Surgery, University of Oklahoma, Oklahoma City, OK
*Purpose: Inter- and intra-individual variability in calcineurin dose requirements necessitates empirical clinician-titrated dosing that frequently results in deviation from target ranges, particularly during the critical…
2021 American Transplant Congress
Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Pediatric Solid Organ Transplant Recipients; Single Center Experience
S. Alharbi¹, A. Aljedai², D. Alkortas²
¹Pharmaceutical Care Division, KFSH&RC, riyadh, Saudi Arabia, ²Pharmaceutical Care Division, KFSH&RC, Riyadh, Saudi Arabia
*Purpose: The main objective of the study is to compare the efficacy of the different Valganciclovir dosing strategies in pediatric solid organ transplant recipients with…
2021 American Transplant Congress
Evaluation of Low Dose Famciclovir as Herpes Simplex Virus and Varicella Zoster Virus Prophylaxis in Cytomegalovirus Low Risk Solid Organ Transplant Recipients
M. Cote, A. Cubley, C. Rogers, S. Shao, C. N. Kotton
Massachusetts General Hospital, Boston, MA
*Purpose: Famciclovir is recommended for herpes simplex virus (HSV) and varicella-zoster virus (VZV) prophylaxis in cytomegalovirus (CMV) low risk (both donor and recipient CMV seronegative)…
2021 American Transplant Congress
Evaluation of Conversion to Extended-Release Tacrolimus in Abdominal Organ and Thoracic Transplant Recipients
A. Diamond¹, N. Agarwal², A. Younas², N. Sifontis², J. Au¹, C. Ruggia-Check¹
¹Pharmacy, Temple University Hospital, Philadelphia, PA, ²Pharmacy, Temple University School of Pharmacy, Philadelphia, PA
*Purpose: An established approach for conversion from immediate-release tacrolimus (IR TAC) to extended-release tacrolimus (LCPT) in kidney transplantation exists, but is lacking in other organ…
2021 American Transplant Congress
Avoiding Tacrolimus Under- and Overexposure with a Dosing Algorithm for Renal Transplant Recipients: A Single Arm Prospective Intervention Trial
M. I. Francke¹, L. M. Andrews², H. L. Le², J. van de Wetering¹, M. C. Clahsen-van Groningen³, T. van Gelder⁴, R. H. van Schaik⁵, B. van der Holt⁶, B. C. de Winter², D. A. Hesselink¹
¹Internal medicine, nephrology and transplantation, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ²Hospital Pharmacy, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ³Pathology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ⁴Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, Netherlands, ⁵Clinical Chemistry, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ⁶Hematology, Erasmus MC, University Medical Center, Rotterdam, Netherlands
*Purpose: Bodyweight-based tacrolimus dosing followed by therapeutic drug monitoring is standard clinical care after renal transplantation. However, after transplantation, a meagre 38% of patients is…
2021 American Transplant Congress
Modeling of Alternative Weight-Based Dosing Strategies of LCP-Tacrolimus in De Novo Kidney Transplant Patients
J. D. Momper¹, S. J. Patel², M. A. Moten², D. R. Stevens², U. Meier-Kriesche²
¹Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, ²Medical Affairs, Veloxis Pharmaceuticals, Cary, NC
*Purpose: LCP-tacrolimus (LCPT; Envarsus XR®) is a modified-release once-daily formulation approved for prophylaxis of organ rejection in de novo kidney transplant patients in combination with…